Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Portugal

Abstract

A343infant in comparison to no-screening strategy. Transferred to the entire birth cohort newborn screening is able to reduce total costs by 14 million € from the Austrian health care systems perspective each year. ConClusions: Funding the new-born screening saves money and is cost-effective for the Austrian health care system.

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy

“…As add-on to metformin, canagliflozin, assessed as a weighted average of 100 and 300 mg, dominated sitagliptin 100 mg in cost-effectiveness analyses conducted in the Swedish, 53 Norwegian, 54 and Portuguese 55 setting. This was also the case for canagliflozin 100 mg, based on economic evaluations in Spain 56 and Poland, 57 whereas canagliflozin 300 mg produced an ICER of €1813 56 and 45,008 zł 57 compared with sitagliptin, respectively.…”

“…In particular, from the Canadian health care perspective, canagliflozin 100 and 300 mg provided QALY gains of 0.28 and 0.31, and cost savings of C$2560 and C$2217, respectively, over a time horizon of 40 years. 68 Canagliflozin also dominated sitagliptin across different countries, including Belgium, 60 France, 59 Norway, 54 and Portugal, 55 when both dosing schemes were assessed as a single intervention. Of note, additional economic evaluations concluded that canagliflozin was a cost-effective therapeutic option as add-on to metformin and sulfonylurea in Brazil, 69 Ireland, 58 Slovakia, 61 and the Czech Republic, 62 although it was associated with higher treatment costs compared with sitagliptin.…”